Levofloxacin might be safe to use for OSCC patients.
Antineoplastic Agents
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Carcinoma, Squamous Cell
/ drug therapy
Cell Line, Tumor
Cell Survival
/ drug effects
Cisplatin
/ administration & dosage
Humans
Levofloxacin
/ administration & dosage
Mouth Neoplasms
/ drug therapy
Tongue Neoplasms
/ drug therapy
Cisplatin
Levofloxacin
Oral squamous cell carcinoma
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
25 Jun 2021
25 Jun 2021
Historique:
received:
11
05
2021
accepted:
15
06
2021
entrez:
25
6
2021
pubmed:
26
6
2021
medline:
28
12
2021
Statut:
epublish
Résumé
Oral squamous cell carcinoma patients are exhausted against the powerful chemotherapies, radiotherapies after the surgery, and their immune system is devastated during the process and antibiotic usage become inescapable. Although prescribing an antibiotic might be fraught for such as drug interaction and undesirable proliferation danger, studies still look for the new ideas such as antibiotic combinations that might be safe to use. The antiproliferative and apoptotic outcomes of levofloxacin with cisplatin combination as well as their single usage were examined with WST-1, Caspase-3/BCA and Annexin V methods on SCC-15 cells and a healthy cell line (MRC-5). 24 h treatment of 50 mM single levofloxacin, 50 mM single cisplatin and 50 mM levofloxacin-cisplatin combination resulted in viability rates of SCC-15 cells as 90%, 67% and 80.8%, respectively. Caspase-3 enzyme activity was enhanced 0.92-fold for single levofloxacin, 13.05-fold for single cisplatin and 9.73-fold for the combination of levofloxacin-cisplatin, the total apoptotic activity of single levofloxacin, single cisplatin and levofloxacin-cisplatin combination were observed as 4.88%, 21.14%, 16.21%, respectively on SCC-15. The apoptotic effect of cisplatin on MRC-5 has been shown to be suppressed when combined with levofloxacin. Considering the cell viability, caspase-3, and apoptotic activity results, it's conclude that the levofloxacin-cisplatin combination was also effective compared to the only cisplatin treatment on OSCC cells. The combination has shown less toxicity for healthy cells than single cisplatin treatment. Therefore, our apoptotic findings suggest that the different dosage combinations are necessary to understand the interaction for the treatment of tongue squamous cell carcinoma.
Identifiants
pubmed: 34170451
doi: 10.1007/s12032-021-01538-2
pii: 10.1007/s12032-021-01538-2
doi:
Substances chimiques
Antineoplastic Agents
0
Levofloxacin
6GNT3Y5LMF
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
87Subventions
Organisme : Bilimsel Araştirma Projeleri Birimi, Istanbul Üniversitesi
ID : 24114
Références
Pan J, Zhao J, Jiang N. Oral cavity infection: an adverse effect after the treatment of oral cancer in aged individuals. J Appl Oral Sci. 2014;22(4):261–7. https://doi.org/10.1590/1678-775720130546 .
doi: 10.1590/1678-775720130546
pubmed: 25141196
pmcid: 4126820
Miguelanez-Medran BC, et al. Oral squamous cell carcinoma of tongue: histological risk assessment. A pilot study. Med Oral Patol Oral Cir Bucal. 2019;24(5):e603–9. https://doi.org/10.4317/medoral.23011 .
doi: 10.4317/medoral.23011
pubmed: 31422411
pmcid: 6764715
Chaturvedi AK, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol. 2013;31(36):4550–9. https://doi.org/10.1200/JCO.2013.50.3870 .
doi: 10.1200/JCO.2013.50.3870
pubmed: 3865341
pmcid: 3865341
Pires FR, et al. Oral squamous cell carcinoma: clinicopathological features from 346 cases from a single oral pathology service during an 8-year period. J Appl Oral Sci. 2013;21(5):460–7. https://doi.org/10.1590/1679-775720130317 .
doi: 10.1590/1679-775720130317
pubmed: 24212993
pmcid: 3881836
Paderno A, Morello R, Piazza C. Tongue carcinoma in young adults: a review of the literature. Acta Otorhinolaryngol Ital. 2018;38(3):175–80. https://doi.org/10.14639/0392-100X-1932 .
doi: 10.14639/0392-100X-1932
pubmed: 29984792
pmcid: 6036956
Selvamani M, et al. Prevalence of oral squamous cell carcinoma of tongue in and around Davangere, Karnataka, India: a retrospective study over 13 years. J Pharm Bioallied Sci. 2015;7(Suppl 2):S491–4. https://doi.org/10.4103/0975-7406.163511 .
doi: 10.4103/0975-7406.163511
pubmed: 26538904
pmcid: 4606646
Sultana J, Bashar A, Molla MR. New management strategies of oral tongue cancer in Bangladesh. J Maxillofac Oral Surg. 2014;13(4):394–400. https://doi.org/10.1007/s12663-013-0566-8 .
doi: 10.1007/s12663-013-0566-8
pubmed: 26225002
Almangush A, et al. Staging and grading of oral squamous cell carcinoma: an update. Oral Oncol. 2020;107: 104799. https://doi.org/10.1016/j.oraloncology.2020.104799 .
doi: 10.1016/j.oraloncology.2020.104799
pubmed: 32446214
Kim YJ, Kim JH. Increasing incidence and improving survival of oral tongue squamous cell carcinoma. Sci Rep. 2020;10(1):7877. https://doi.org/10.1038/s41598-020-64748-0 .
doi: 10.1038/s41598-020-64748-0
pubmed: 32398670
pmcid: 7217912
Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–78. https://doi.org/10.1016/j.ejphar.2014.07.025 .
doi: 10.1016/j.ejphar.2014.07.025
pubmed: 25058905
pmcid: 4146684
Yoshikawa K, et al. The Hippo pathway transcriptional co-activator, YAP, confers resistance to cisplatin in human oral squamous cell carcinoma. Int J Oncol. 2015;46(6):2364–70. https://doi.org/10.3892/ijo.2015.2948 .
doi: 10.3892/ijo.2015.2948
pubmed: 25846049
Bayat Mokhtari R, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022–43. https://doi.org/10.18632/oncotarget.16723 .
doi: 10.18632/oncotarget.16723
pubmed: 28410237
Dong Z, et al. Biological functions and molecular mechanisms of antibiotic tigecycline in the treatment of cancers. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20143577 .
doi: 10.3390/ijms20143577
pubmed: 31817689
pmcid: 6941021
Yadav V, Talwar P. Repositioning of fluoroquinolones from antibiotic to anti-cancer agents: an underestimated truth. Biomed Pharmacother. 2019;111:934–46. https://doi.org/10.1016/j.biopha.2018.12.119 .
doi: 10.1016/j.biopha.2018.12.119
pubmed: 30841473
Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect Dis. 2003;3(6):359–71. https://doi.org/10.1016/s1473-3099(03)00658-3 .
doi: 10.1016/s1473-3099(03)00658-3
pubmed: 12781508
Oliphant CM, et al. Quinolones: a comprehensive review. Am Fam Physician. 2002;65(3):455–64.
pubmed: 11858629
Izadi E, et al. Levofloxacin: insights into antibiotic resistance and product quality. Front Pharmacol. 2019;10:881. https://doi.org/10.3389/fphar.2019.00881 .
doi: 10.3389/fphar.2019.00881
pubmed: 31474853
pmcid: 6702332
Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet. 1997;32(2):101–19. https://doi.org/10.2165/00003088-199732020-00002 .
doi: 10.2165/00003088-199732020-00002
pubmed: 9068926
Gouvea LR, et al. Atypical fluoroquinolone gold(III) chelates as potential anticancer agents: relevance of DNA and protein interactions for their mechanism of action. Eur J Med Chem. 2012;55:67–73. https://doi.org/10.1016/j.ejmech.2012.07.004 .
doi: 10.1016/j.ejmech.2012.07.004
pubmed: 22835721
Kljun J, et al. New uses for old drugs: attempts to convert quinolone antibacterials into potential anticancer agents containing ruthenium. Inorg Chem. 2013;52(15):9039–52. https://doi.org/10.1021/ic401220x .
doi: 10.1021/ic401220x
pubmed: 23886077
Mondal ER, Das SK, Mukherjee P. Comparative evaluation of antiproliferative activity and induction of apoptosis by some fluoroquinolones with a human non-small cell lung cancer cell line in culture. Asian Pac J Cancer Prev. 2004;5(2):196–204.
pubmed: 15244525
Song M, et al. Antibiotic drug levofloxacin inhibits proliferation and induces apoptosis of lung cancer cells through inducing mitochondrial dysfunction and oxidative damage. Biomed Pharmacother. 2016;84:1137–43. https://doi.org/10.1016/j.biopha.2016.10.034 .
doi: 10.1016/j.biopha.2016.10.034
pubmed: 27780143
Yoshimura T, et al. Immunomodulatory action of levofloxacin on cytokine production by human peripheral blood mononuclear cells. Chemotherapy. 1996;42:459–64. https://doi.org/10.1159/000239480 .
doi: 10.1159/000239480
pubmed: 8957581
Yu M, Li R, Zhang J. Repositioning of antibiotic levofloxacin as a mitochondrial biogenesis inhibitor to target breast cancer. Biochem Biophys Res Commun. 2016;471(4):639–45. https://doi.org/10.1016/j.bbrc.2016.02.072 .
doi: 10.1016/j.bbrc.2016.02.072
pubmed: 26902121
Korolyov A, et al. Novel lipophilic 7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid derivatives as potential antitumor agents: improved synthesis and in vitro evaluation. Bioorg Med Chem. 2010;18(24):8537–48. https://doi.org/10.1016/j.bmc.2010.10.039 .
doi: 10.1016/j.bmc.2010.10.039
pubmed: 21067931
Sun J-P, et al. Trimethoxy-benzaldehyde levofloxacin hydrazone inducing the growth arrest and apoptosis of human hepatocarcinoma cells. Cancer Cell Int. 2013;13(1):67. https://doi.org/10.1186/1475-2867-13-67 .
doi: 10.1186/1475-2867-13-67
pubmed: 23819802
pmcid: 3716872
Masrour-Roudsari J, Ebrahimpour S. Causal role of infectious agents in cancer: an overview. Casp J Intern Med Summer. 2017;8(3):153–8. https://doi.org/10.22088/cjim.8.3.153 .
doi: 10.22088/cjim.8.3.153
Petrelli F, et al. Use of antibiotics and risk of cancer: a systematic review and meta-analysis of observational studies. Cancers (Basel). 2019;11(8):1174. https://doi.org/10.3390/cancers11081174 .
doi: 10.3390/cancers11081174
Charshafian S, Liang SY. Rapid fire: infectious disease emergencies in patients with cancer. Emerg Med Clin N Am. 2018;36(3):493–516. https://doi.org/10.1016/j.emc.2018.04.001 .
doi: 10.1016/j.emc.2018.04.001
Villagómez-Ortíz VJ, et al. Prevalence of human papillomavirus infection in squamous cell carcinoma of the oral cavity, oropharynx and larynx. Cirugía y Cirujanos (Engl Ed). 2016;84(5):363–8. https://doi.org/10.1016/j.circir.2016.01.006 .
doi: 10.1016/j.circir.2016.01.006
Blatt S, et al. Biomarkers in diagnosis and therapy of oral squamous cell carcinoma: a review of the literature. J Cranio-Maxillofac Surg. 2017;45(5):722–30. https://doi.org/10.1016/j.jcms.2017.01.033 .
doi: 10.1016/j.jcms.2017.01.033
Ettinger KS, Ganry L, Fernandes RP. Oral cavity cancer. Oral Maxillofac Surg Clin N Am. 2019;31(1):13–29. https://doi.org/10.1016/j.coms.2018.08.002 .
doi: 10.1016/j.coms.2018.08.002
Omura K. Current status of oral cancer treatment strategies: surgical treatments for oral squamous cell carcinoma. Int J Clin Oncol. 2014;19:423–30. https://doi.org/10.1007/s10147-014-0689-z .
doi: 10.1007/s10147-014-0689-z
pubmed: 24682763
Qi L, et al. Advances in toxicological research of the anticancer drug cisplatin. Chem Res Toxicol. 2019;32:1469–86. https://doi.org/10.1021/acs.chemrestox.9b00204 .
doi: 10.1021/acs.chemrestox.9b00204
pubmed: 31353895
Al-Bahlani SM, et al. Cisplatin induces apoptosis via ER-mediated, calpain1 pathway in triple negative breast cancer cells. Clin Breast Cancer. 2017;17(3):e103–12. https://doi.org/10.1016/j.clbc.2016.12.001 .
doi: 10.1016/j.clbc.2016.12.001
pubmed: 28089626
Kleih M, et al. Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells. Cell Death Dis. 2019;10(11):851. https://doi.org/10.1038/s41419-019-2081-4 .
doi: 10.1038/s41419-019-2081-4
pubmed: 31699970
pmcid: 6838053
Shi S, et al. ER stress and autophagy are involved in the apoptosis induced by cisplatin in human lung cancer. Oncol Rep. 2016;35(5):2606–14. https://doi.org/10.3892/or.2016.4680 .
doi: 10.3892/or.2016.4680
pubmed: 26985651
pmcid: 4811398
Pezeshki Z, et al. Time course of cisplatin-induced nephrotoxicity and hepatotoxicity. J Nephropathol. 2017;6:163–7. https://doi.org/10.15171/jnp.2017.28 .
doi: 10.15171/jnp.2017.28
pubmed: 28975096
pmcid: 5607978
Tsang RY, Al-Fayea T, Au H-J. Cisplatin overdose toxicities and management. Drug Saf. 2009;32(12):1109–22. https://doi.org/10.2165/11316640-000000000-00000 .
doi: 10.2165/11316640-000000000-00000
pubmed: 19916578
Bhatia K, Bhumika DA. Combinatorial drug therapy in cancer-New İnsights. Life Sci. 2020;258:118–34. https://doi.org/10.1016/j.lfs.2020.118134 .
doi: 10.1016/j.lfs.2020.118134
Bhattacharya B, Mukherjee S. Cancer therapy using antibiotics. J Cancer Ther. 2015;6:849–58. https://doi.org/10.4236/jct.2015.610093 .
doi: 10.4236/jct.2015.610093
AlKhalil M, et al. Selected pharmacotherapy agents as antiproliferative and anti-inflammatory compounds. Drug Dev Res. 2020;81(4):470–90. https://doi.org/10.1002/ddr.21640 .
doi: 10.1002/ddr.21640
pubmed: 31943302
He L, et al. Once-daily, oral levofloxacin monotherapy for low-risk neutropenic fever in cancer patients: a pilot study in China. Anticancer Drugs. 2015;26:359–62. https://doi.org/10.1097/CAD.0000000000000187 .
doi: 10.1097/CAD.0000000000000187
pubmed: 25486597
pmcid: 4314102
Olson J, et al. Oral step-downtherapy with levofloxacin for febrile neutropenia in children with cancer. J Pediatr Infect Dis Soc. 2021;10(1):27–33. https://doi.org/10.1093/jpids/piaa015 .
doi: 10.1093/jpids/piaa015